The μ-opioid receptor

Pain Reviews

Volumn 3, Issue 4, 1996, Pages 221-248

  Traynor, J R ^a,b  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA FUNALTREXAMINE; BUPRENORPHINE; CODEINE; DIAMORPHINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALOXONAZINE; NALOXONE; PENTAZOCINE; PETHIDINE;

AMINO ACID SEQUENCE; DRUG EFFECT; HUMAN; NOCICEPTION; PAIN; PROTEIN STRUCTURE; REVIEW;

EID: 0030469897     PISSN: 09681302     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-32.
2. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature 1977; 267: 495-99.
3. Paterson SJ, Robson RE, Kosterlitz HW. Classification of opioid receptors. Br Med Bull 1983; 39: 31-36.
4. Uhl GR, Childers S, Pasternak G. An opiate-receptor gene family reunion. Trends Neurosci 1994; 17: 89-93.
5. Kenakin T. Pharmacologic analysis of drug receptor interactions. New York: Raven Press, 1993: 249-77.
6. Leslie FM. Methods used for the study of opioid receptors. Pharmacol Rev 1987; 39: 197-249.
7. Ward SJ, Lopresti D, James DW. Activity of muand delta-selective opioid agonists in the guinea-pig ileum preparation: differentiation into peptide and non-peptide classes with β-funaltrexamine. J Pharmacol Exp Ther 1986; 238: 625-31.
8. Smith CFC, Rance MJ. Opiate receptors in rat vas deferens. Life Sci 1983; 33(suppl 1): 327-30.
9. Magnan J, Paterson SJ, Tavani A, Kosterlitz HW. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch Pharmacol 1982; 319: 197-205.
10. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 1983; 33(suppl 1): 773-76.
11. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1995; 47: 848-54.
12. Hayes AG, Tyers M. Determination of receptors that mediate opiate side-effects in the mouse. Br J Pharmacol 1983; 79: 731-36.
13. Foley KM. Opioid analgesics in clinical pain management. In: Herz A ed. Handbook of experimental pharmacology, vol. opioids II. Heidelberg: Springer, 1993: 697-743.
14. Houde RW. Analgesic effectiveness of the narcotic-agonist antagonists. Br J Clin Pharmacol 1979; 7: 297S-308S.
15. Robbie DS. A trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmcol 1979; 7: 315S-17S.
16. Jacob JJC, Michaud GM, Tremblay EC. Mixed agonist-antagonist opiates and physical dependence. Br J Clin Pharmacol 1979; 7: 291S-96S.
17. Negus SS, Woods JH. Reinforcing effects, discriminative stimulus effects, and physical dependence liability of buprenorphine. In: Cowan A, Lewis JW eds. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 71-101.
18. Villiger JW. Binding of buprenorphine to opiate receptors: regulation by guanyl nucleotides and metal ions. Neuropharmacology 1984; 23: 373-75.
19. Cowan A. Update on the general pharmacology of buprenorphine. In: Cowan A, Lewis JW eds. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 31-47.
20. Bovill JG, Sebel PS, Stanley TH. Opioid analgesics in anaesthesia: with special reference to their use in cardiovascular anaesthesia. Anaesthesiology 1984; 61: 731-55.
21. Stanley TH. High-dose narcotic anesthesia. Semin Anesth 1982; 21: 21-32.
22. Hughes S, Higgs NB, Turnberg LA. Loperamide has antisecretory activity in the human jejunum in vivo. Gut 1981; 25: 931-35.
23. Wuster M, Herz A. Opiate agonist action of antidiarrhoeal agents in vitro and in vivo - findings in support of selective action. Naunyn-Schmiedeberg's Arch Pharmacol 1978; 301: 187-94.
24. Miyazake H, Nambu K, Hashimoto M. Loperamide in rat intestines: a unique disposition. Life Sci 1982; 30: 2203-206.
25. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from brain with potent opiate agonist activity. Nature 1975; 258: 577-79.
26. Bradbury AF, Smyth DG, Snell CR, Birdsall NJM, Hulme EC. C fragment of lipotrophin has a high affinity for brain opiate receptors. Nature 1976; 260: 793-95.
27. Goldstein A, Fischli W, Lowrey LI, Hunkapillar M, Hood L. Porcine pituitary dynorphin: complete amino-acid sequence of the biologically active heptapeptide. Proc Natl Acad Sci USA 1981; 78: 7219-23.
28. 61-64 possessing selective agonist activity at μ-opiate receptors. Eur J Pharmacol 1981; 70: 531-40.
29. Tyers MB. A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol 1980; 69: 503-12.
30. Skingle M, Tyers MB. Further studies on opiate receptors that mediate antinociception: tooth pulp stimulation in the dog. Br J Pharmacol 1980; 70: 323-27.
31. 3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain. J Pharmacol Exp Ther 1989; 248: 73-80.
32. Hayes AG, Skingle M, Tyers MB. Reversal by β-funaltrexamine of the antinociceptive effect of opioid agonists in the rat. Br J Pharmacol 1986; 88: 867-72.
33. Zimmerman DM, Leander JD, Reel JK, Hynes MD. Use of β-funaltrexamine to determine mu-opioid receptor involvement in the analgesic activity of various opioid ligands. J Pharmacol Exp Ther 1987; 241: 374-78.
34. Hayes AG, Birch PJ. Reversal by β-funaltrexamine and 16-methyl cyprenorphine of the antinociceptive effects of opioid agonists in the mouse and guinea-pig. Neuropharmacology 1988; 27: 813-16.
35. Garzon J, Sanchez-Blazquez P. In vivo injection of antibodies directed against the cloned μ-opioid receptor blocked supraspinal analgesia induced by μ-agonists in mice. Life Sci 1995; 56: PL237-42.
36. Pasternak GW, Wood PJ. Multiple opiate receptors. Life Sci 1986; 38: 1889-98.
37. Ling GSF, Spiegel K, Lockhart SH, Pasternak GW. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther 1985; 232: 149-55.
38. Heyman JS, Williams CL, Burks TF, Mosberg HI, Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse - studies with naloxonazine. J Pharm Exp Ther 1988; 245: 238-49.
39. 2 opioid actions. Life Sci 1991; 48: 2005-2011.
40. Pick CG, Nejat RJ, Pasternak GW. Independent expression of two pharmacologically distinct supraspinal μ-analgesia systems in genetically different mouse strains. J Pharmacol Exp Ther 1993; 265: 166-71.
41. Fowler FJ, Fraser GL. μ-, δ-, κ-Opioid receptors and their subtypes. A critical review with emphasis on radioligand binding experiments. Neurochem Int 1994; 24: 401-26.
42. Evans JC, Keith DE, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-55.
43. Kieffer BL, Befort K, Gaveriaux-Ruft C, Hirth CG. The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterisation. Proc Natl Acad Sci USA 1992; 89: 12048-52.
44. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol Pharmacol 1993; 44: 8-12.
45. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H. Primary structures and expression from cDNAs of rat opioid receptor δ and μ subtypes. FEBS Lest 1993; 327: 311-14.
46. Thompson RC, Mansour A, Akil H, Watson SJ. Cloning and pharmacological characterisation of a rat μ-opioid receptor. Neuron 1993; 11: 903-13.
47. Wang JB, Imai Y, Eppler CM, Gregor P, Spirak CE, Uhl GR. μ-Opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci USA 1993; 90: 10230-34.
48. Zastawny RL, George SR, Nguyen T et al. Cloning, characterisation and distribution of a μ-opioid receptor in rat brain. J Neurochem 1994; 62: 2099-105.
49. Bunzow JR, Zhang Ge, Bouvier C et al. Characterisation and distribution of a cloned rat μ-opioid receptor. J Neurochem 1995; 64: 14-24.
50. Minami M, Onogi T, Toya T et al. Molecular cloning and in situ hybridisation histochemistry for rat μ-opioid receptor. Neurosci Res 1994; 18: 315-22.
51. Kaufman DL, Keith DE, Anton B et al. Characterisation of the murine μ-opioid receptor gene. J Biol Chem 1995; 279: 15877-83.
52. Wang J-B, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human μ opiate receptor. FEBS Lett 1994; 338: 217-22.
53. Mestek A, Hurley JH, Bye LS et al. The human μ opioid receptor: modulation of functional desensitisation by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci 1995; 15: 2396-406.
54. Childers SR. Opioid receptor-coupled second messenger systems. Life Sci 1991; 48: 1991-2003.
55. Langwitz K-H, Offermanns S, Spicher K, Schultz G. μ and δ opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron 1993; 10: 233-42.
56. 32P-α-azidoanilide GTP labelling of multiple G protein a subunits. J Neurochem 1995; 6: 2534-43.
57. Wollemann M. Recent developments in the research of opioid receptor subtype molecular characterisation. J Neurochem 1990; 54: 1095-101.
58. Loh HH, Smith AP. Molecular characterisation of opioid receptors. Annu Rev Pharmacol Toxicol 1990; 30: 123-47.
59. Miotto K, Magendzo K, Evans CJ. Molecular characterisation of opioid receptors. In: Tseng LF ed. The pharmacology of opioid peptides. Germany: Harwood Academic Publishers, 1995: 57-72.
60. Surratt CK, Johnson PS, Moriwaki A et al. μ-Opiate receptor: charged transmembrane domain amino-acids are critical for agonist recognition and intrinsic activity. J Biol Chem 1994; 269: 20548-53.
61. Milligan G, Parenti M, Magee AI. The dynamic role of palmitoylation in signal transduction. Trends Biochem Sci 1995; 20: 181-86.
62. Smith JR, Simon EJ. Selective protection of stereospecific enkephalin and opiate binding against inactivation by N-ethylmaleimide: evidence for two classes of opiate receptors. Proc Natl Acad Sci USA 1980; 77: 281-84.
63. Strader CD, Sigal IS, Dixon RAF. Structural basis for β-adrenergic receptor function. FASEB J 1989; 3: 1825-32.
64. 1-adrenergic receptor involved in coupling to phosphatidyl inositol hydrolysis and enhanced sensitivity to biological function. Proc Natl Acad Sci USA 1990; 87: 2896-900.
65. Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC. Sequence alignment of G protein coupled receptor family. DNA Cell Biol 1992; 11: 1-20.
66. Prossnitz ER, Quehenberger O, Cochrane CG, Ye RD. The role of the third intracellular loop of the neutrophil N-formyl peptide receptor in G protein coupling. Biochem J 1993; 294: 581-87.
67. Schreiber RE, Prossnitz ER, Ye RD, Cochrane CG, Bokoch GM. Domains of the human neutrophil N-formyl peptide receptor involved in G protein coupling. J Biol Chem 1994; 269: 326-31.
68. Raynor K, Kong H, Mestek A et al. Characterisation of the cloned human μ-opioid receptor. J Pharmacol Exp Ther 1995; 272: 423-28.
69. Kong H, Raynor K, Yasuda K et al. A single residue, aspartic acid 95, in the δ opioid receptor specifies selective high affinity agonist binding. J Biol Chem 1993; 268: 23055-58.
70. Shahrestanifor M, Wang WW, Howells RD. Studies on inhibition of μ-opioid and δ-opioid receptor binding by dithiothreitol and N-ethymaleimide - His 223 is critical for μ-opioid receptor binding and inactivation by N-ethylmaleimide. J Biol Chem 1996; 271: 5505-12.
71. Befort K, Tabbara L, Bausch S, Charkin C, Evans SC, Keiffer B. The conserved aspartate residue in the 3rd transmembrane domain of the δ-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constitutent of the receptor binding site. Mol Pharmacol 1996; 49: 216-23.
72. Claude PA, Wotta DR, Zhang XH et al. Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proc Natl Acad Sci USA 1996; 93: 5715-19.
73. Wang JB, Inai Y, Eppler CM, Gregor P, Spivak CE, Uhl GR. Deletion of 64 N-terminal amino acids produced little effect on receptor function. Proc Natl Acad Sci USA 1993; 90: 10230-34.
74. Wang WW, Shahrestanifor M, Jin J, Howells RD. Studies on mu-opioid and delta-opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proc Natl Acad Sci USA 1995; 92: 12436-40.
75. Onogi T, Minami M, Katao Y et al. Damgo, a μ-opioid receptor agonist distinguishes between μ-opioid and δ-opioid receptors around their first intracellular loops. FEBS Lett 1995; 357: 93-97.
76. Xue JC, Chen CG, Zhu JM et al. The 3rd extracellular loop of the μ-opioid receptor is important for agonist selectivity. J Biol Chem 1995; 270: 12977-79.
77. Zhu JM, Xue JC, Law P-Y et al. The region in the mu-opioid receptor conferring selectivity for sufentanil over the delta-receptor is different from that over the kappa-receptor. FEBS Lett 1996; 384: 198-202.
78. Elliott J, Smart D, Lambert DG, Traynor JR. Characterisation of μ-opioid receptors on SH-SY5Y cells using naloxonazine and β-funaltrexamine. Eur J Pharmacol Mol Pharmacol 1994; 268: 447-50.
79. Bore AL, Mansson E, Yang D. Expression of two variants of the human μ-opioid receptor messenger RNA in SK-N-SH cells and human brain. FEBS Lett 1994; 354: 213-16.
80. Zimprich A, Simon T, Höllt V. Cloning and expression of an isoform of the rat μ opioid receptor (rMOR1B) which differs in agonist induced desensitisation from rMOR1. FEBS Lett 1995; 359: 142-46.
81. Mayer P, Schulzeck S, Kraus J, Zimprich A, Holt V. Promoter region and alternatively spliced exons of the rat mu-opioid receptor gene. J Neurochem 1996; 66: 2272-78.
82. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol Sci 1994; 15: 42-46.
83. Standifer KM, Chen XH, Wahlestedt C, Brown GP, Pasternak GW. Selective loss of δ opioid analgesia and binding by antisense oligonucleotide to a δ opioid receptor. Neuron 1994; 12: 805-10.
84. Rossi GC, Pan YX, Cheng J, Pasternak GW. Blockade of morphine analgesia by an antisense oligonucleotide against the μ receptor. Life Sci 1994; 54: PL375-79.
85. Chen XH, Adams JU, Geller E, DeReil JK, Adler M, Liu-Chen L-Y. An antisense oligonucleotide to μ-opioid receptors inhibits μ-opioid receptor agonist-induced analgesia in rats. Eur J Pharmacol 1995; 275: 105-108.
86. Rossi GC, Pan YX, Brown GP, Pasternak GW. Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6β-glucuronide receptor. FEBS Lett 1995; 369: 192-96.
87. Paul D, Standifer KM, Inturrisi C, Pasternak GW. Pharmacological characterisation of morphine-6β-glucuronide: a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251: 477-83.
88. Frances B, Gout R, Monsarrat B, Cros J, Zajac J-M. Further evidence that morphine-6β-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 1992; 262: 25-31.
89. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet 1988; i: 828.
90. Hand CW, Blunnie WP, Claffrey LP, McShane AJ, McQuay HJ, Moore RA. Morphine-6-glucuronide in CSF after IM and oral administration: potential analgesia contribution from this metabolite. Lancet 1987; ii: 1207-208.
91. Mansour A, Fox CA, Thompson RC, Akil H, Watson SJ. Mu-opioid receptor mRNA expression in the rat CNS: comparison to mu receptor binding. Brain Res 1994; 643: 245-65.
92. Mansour A, Fox CA, Burke S, Akil H, Watson SJ. Immunohistochemical localisation of the cloned μ opioid receptor in the rat CNS. J Chem Neuroanat 1995; 8: 283-305.
93. Arvidsson U, Reidl M, Chakrabarti S et al. Distribution and targeting of a μ-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 1995; 15: 3328-41.
94. Delfs JM, Kong H, Mestek A, Chen Y, Yu L, Reisine T, Chesselet M-F. Expression of mu opioid receptor mRNA in rat brain: an in situ hybridisation study at the single cell level. J Comp Neurol 1994; 345: 46-68.
95. Illes P. Modulation of transmitter and hormone release by multiple neuronal opioid receptors. Rev Physiol Biochem Pharmacol 1989; 112: 139-233.
96. Tsou K, Jang CS. Studies on the site of analgesic action of morphine by intracerebral microinjection. Scientia Sinica 1964; 13: 1099-109.
97. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991; 14: 219-45.
98. Grudt TJ, Williams JT. Mu-opioid agonists inhibit spinal trigeminal substantia-gelatinosa neurons in guinea-pig and rat. J Neurosci 1994; 14: 1646-54.
99. Besse D, Lombard MC, Zajac JM, Roques BP, Besson JM. Pre- and postsynaptic distribution of μ, δ and κ opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res 1990; 251: 15-22.
100. Stein C. Peripheral mechanisms of opioid analgesia. Anesth Analg 1993; 76: 182-92.
101. Schafer M, Imai Y, Uho GR, Stein C. Inflammation enhances peripheral μ-opioid receptor-mediated analgesia, but not μ-opioid receptor transcription in dorsal root ganglia. Eur J Pharmacol 1995; 279: 165-69.
102. Hassan AHS, Ableitner A, Stein C, Herz A. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 1993; 55: 185-95.
103. Cohen GA, Doze UA, Madison DV. Opioid inhibition of GABA release from presynaptic terminals of rat hippocampal interneurons. Neuron 1992; 9: 325-35.
104. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor message-RNA expression in the rat CNS - anatomical and functional implications. Trends Neurosci 1995: 18: 22-29.
105. Birmbaumer L, Abramowitz J, Brown AM. Receptor-effector coupling by G proteins. Biochim Biophys Acta 1990; 1031: 163-224.
106. Sternweiss PC. The active role of βγ in signal transduction. Curr Opin Cell Biol 1994; 6: 198-203.
107. Clapham DE, Neer EJ. New roles for βγ-dimers in transmembrane signalling. Nature 1993; 269: 403-406.
108. Gunderman T, Kalkbrenner F, Schultz G. Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol 1996; 36: 429-59.
109. Katada TM, Oinuma M, Ui M. Mechanism for inhibition of the catalytic activity of adenylate cyclase by the guanine nucleotide-binding proteins serving as the substrate for islet-activating protein, pertussis toxin. J Biol Chem 1986; 261: 5215-21.
110. Carroll JA, Shaw JS, Wickenden AD. The physiological relevance of low agonist affinity binding at opioid μ-receptors. Br J Pharmacol 1988; 94: 625-31.
111. Werling LL, Putfarken PS, Cox BM. Multiple agonist-affinity states of opioid receptors: regulation of binding by guanyl nucleotides in guinea-pig cortical, NG8-15 and 7315c cell membranes. Mol Pharmacol 1988; 33: 423-31.
112. Carter BD, Medzihradsky F. Opioid signal transduction in intact and fragmented SH-SY5Y neural cells. J Neurochem 1992; 58: 1611-19.
113. Carter BD, Medzihradsky F. Go mediates the coupling of the μ-opioid receptor to adenylyl cyclase in cloned neural cells and brain. Proc Natl Acad Sci USA 1993; 90: 4063-66.
114. Moises HC, Rusin KI, Macdonald RL. μ-Opioid receptor-mediated reduction of neuronal calcium current occurs via a Go-type GTP-binding protein. J Neurosci 1994; 14: 3842-51.
115. Ueda H, Harada H, Nozaki M et al. Reconstitution of rat brain μ opioid receptors with purified guanine nucleotide binding regulatory proteins, Gi and Go. Proc Natl Acad Sci USA 1988; 85: 7013-17.
116. Ueda H, Misawa H, Katada T, Ui M, Takagi H, Satoh M. Functional reconstitution of purified Gi and Go with μ-opioid receptors in guinea-pig striatal membranes treated with micromolar concentrations of N-ethylmaleimide. J Neurochem 1990; 54: 841-48.
117. 2+ mobilisation. Neuroreport 1995; 7: 54-56.
118. Przewlocki R, Costa T, Lang J, Herz A. Pertussis toxin abolishes the antinociception mediated by opioid receptors in rat spinal cord. Eur J Pharmacol 1987; 144: 91-95.
119. Parenti M, Tirone F, Giagnoni G, Peroca N, Parolaro D. Pertussis toxin inhibits the antiociceptive action of morphine in the rat. Eur J Pharmacol 1986; 124: 357-59.
120. Raffa RB, Martinez RP, Connelly CD. G-Protein antisense oligonucleotides and μ-opioid supraspinal actinociception. Eur J Pharmacol 1994; 258: R5-R7.
121. Sanchez-Blazquez P, Garciaespana A, Garzon J. In-vivo injection of antisense oligodeoxynucleotides to G-alpha subunits and supraspinal analgesia evoked by mu-opioid and delta-opioid agonists. J Pharmacol Exp Ther 1995; 275: 1590-96.
122. 2+ channel current in differentiated SH-SY5Y neuroblasotoma cells. Proc R Soc Lond [Biol] 1991; 244: 129-35.
123. Williams JT, North RA, Tokimasa T. Inward rectification of resting and opiate-activated potassium currents in rat locus ceruleus neurons. J Neurosci 1988; 8: 4299-306.
124. Schultz G, Rosenthal W, Hescheler J, Trautwein W. Role of G proteins in calcium channel modulation. Annu Rev Physiol 1990; 52: 275-92.
125. Nestler EJ. Cellular responses to chronic treatment with drugs of abuse. Crit Rev Neurobiol 1993; 7: 23-39.
126. Di Chiara G, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992; 13: 185-93.
127. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarisation of local interneurons. J Neurosci 1992; 12: 483-88.
128. Crain SM, Shen K-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci 1990; 11: 77-81.
129. Exton JH. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters and other agonists linked to G proteins. Annu Rev Pharmacol Toxicol 1996; 36: 481-509.
130. Smart D, Smith G, Lambert DG. μ-Opioid receptor stimulation of inositol(1,3,5)triphosphate formation via a pertussis toxin sensitive G protein. J Neurochem 1994; 62: 1009-14.
131. Smart D, Smith G, Lambert DG. μ-Opioids activate phospholipase C in SH-SY5Y human neuroblastoma cells via calcium channel opening. Biochem J 1995; 305: 577-87.
132. Connor M, Henderson G. δ- and μ-opioid receptor mobilisation of intracellular calcium in SH-SY5Y human neuroblastoma cells. Br J Pharmacol 1996; 117: 333-40.
133. Adams J, Holtzman SR. Tolerance and dependence after continuous morphine infusion from osmotic pumps measured by operant responding in rats. Psychopharmacology 1990; 100: 451-58.
134. Christie MJ, Williams JT, North RA. Cellular mechanisms of opioid tolerance: studies in single brain neurons. Mol Pharmacol 1987; 32: 633-38.
135. Yu VC, Sadee W. Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells. J Pharmacol Exp Ther 1988; 245: 350-55.
136. Kennedy C, Henderson G. μ-Opioid receptor inhibition of calcium current: development of homologous tolerance in single SH-SY5Y cells after chronic exposure to morphine in vitro. Mol Pharmacol 1991; 40: 1000-1005.
137. Puttfarken PS, Werling LL, Cox BM. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at μ-opioid receptors. Mol Pharmacol 1988; 33: 520-27.
138. Fiorillo CD, Williams JT. Opioid desensitization - interactions with G-protein-coupled receptors in the locus coeruleus. J Neurosci 1996; 16: 1479-85.
139. Prather PL, Tsai AW, Law P-Y. Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SH-SY5Y cells. J Pharmacol Exp Ther 1994; 270: 177-84.
140. Zadina JE, Chang SL, Ge L-J, Kasstin AJ. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells. J Pharmacol Exp Ther 1993; 264: 254-62.
141. Höllt V, Dum J, Blasig J, Schubert P, Herz A. Comparison of in vivo and in vitro parameters of opiate receptor binding in naive and tolerant/ dependent rats. Life Sci 1975; 16: 1823-28.
142. Klee WA, Streaty RA. Narcotic receptor sites in morphine-dependent rats. Nature 1974; 248: 61-63.
143. Simon EJ, Miller JB. In vitro studies on opiate receptors and their ligands. Fed Proc 1978; 37: 141-46.
144. Werling LL, McMahon PN, Cox BM. Selective changes in mu opioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci USA 1989; 86: 6393-97.
145. Tao P-L, Lay P-Y, Loh HH. Decrease in δ and μ-opioid receptor binding capacity in brain after chronic etorphine treatment. J Pharmacol Exp Ther 1987; 240: 809-16.
146. Tao P-L, Lee HY, Chang L-R, Loh HH. Decrease in mu-opioid receptor binding capacity in rat brain after chronic PLO-17 treatment. Brain Res 1990; 526: 270-75.
147. Tempel A, Habas JE, Paredes W, Barr GA. Morphine-induced down-regulation of μ-opioid receptors in neonatal rat brain. Brain Res 1988; 469: 129-33.
148. Tao P-L, Lee C-R, Law P-Y, Loh HH. The interaction of the mu-opioid receptor and G protein is altered after chronic morphine treatment in rats. Naunyn-Schmiederbergs Arch Pharmacol 1993; 348: 504-508.
149. Wang C-S, Su Y-F, Watkins WD, Chang KJ. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes. J Pharmacol Exp Ther 1992; 262: 317-26.
150. Noble F, Cox BM. Differential desensitisation of μ-opioid and δ-opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol 1996; 117: 161-69.
151. Ammer H, Schultz R. Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low-efficacy μ-opioids. Biochem J 1993; 295: 263-71.
152. Nestler EJ, Erdos JJ, Terwilliger R, Duman RS, Tallman JF. Regulation of G-proteins by chronic morphine in the rat locus coeruleus. Brain Res 1989; 476: 230-39.
153. Hausdorff WP, Caron MC, Lefkowitz RJ. Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J 1990; 402: 2881-89.
154. Arden JR, Segredo V, Wang Z, Lameh J, Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged μ-opioid receptor expressed in HEK cells. J Neurochem 1995; 65: 1636-45.
155. 2+-dependent. FEBS Lett 1996; 387: 53-57.
156. Zhang L, Yu YK, Mackin S, Weight FF, Uhl GR, Wang JB. Differential μ-opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J Biol Chem 1996; 271: 11449-54.
157. Wang Z, Bilsky EJ, Porreca F, Sadee W. Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 1994; 54: PL339-50.
158. Lefkowitz RJ, Cotecchia S, Samama P, Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993; 14: 303-307.
159. 2 and protein kinase inhibitors H7 and H8 on acute morphine-dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 1996; 277: 484-90.